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What is the key question? 
 
What effects do HIV infection and anti-retroviral therapy (ART) have on tuberculosis 
(TB) risk in children? 
What is the bottom line? 
 
HIV infection increases the incidence of TB in children by a factor of around 8, 
increasing with degree of immunosuppression; ART reduces TB risk by around 70%, 
with protection continuing to increase over 1-2 years.  
Why read on? 
 
TB incidence in HIV infected children is very high, but no systematic review has 
quantified the effects of HIV or ART on TB risk in children. 
 
 
  
ABSTRACT  
 
 
Background Children (<15 years) are vulnerable to tuberculosis (TB) disease 
following infection, but no systematic review or meta-analysis has quantified the 
effects of HIV-related immunosuppression or antiretroviral therapy (ART) on their 
TB incidence.  
 
Objectives Determine the impact of HIV infection and ART on risk of incident TB 
disease in children. 
 
Methods We searched MEDLINE and Embase for studies measuring HIV prevalence 
in paediatric TB cases (‘TB cohorts’) and paediatric HIV cohorts reporting TB 
incidence (‘HIV cohorts’). Study quality was assessed using the Newcastle-Ottawa 
tool. TB cohorts with controls were meta-analysed to determine the incidence rate 
ratio (IRR) for TB given HIV. HIV cohort data were meta-analysed to estimate the 
trend in log-IRR versus CD4 percentage, relative incidence by immunological stage, 
and ART-associated protection from TB. 
 
Results 42 TB cohorts and 22 HIV cohorts were included. In the eight TB cohorts 
with controls, the IRR for TB was 7.9 (95% confidence interval [CI]: 4.5-13.7). HIV-
infected children exhibited a reduction in IRR of 0.94 (95% credible interval: 0.83-
1.07) per percentage point increase in CD4%. TB incidence was 5.0 (95%CI: 4.0-6.0) 
times higher in children with severe compared to non-significant immunosuppression. 
TB incidence was lower in HIV-infected children on ART (hazard ratio: 0.30; 95%CI: 
0.21-0.39). Following initiation of ART, TB incidence declined rapidly over 12 
months towards a hazard ratio of 0.10 (95%CI: 0.04-0.25). 
 
Conclusions HIV is a potent risk factor for paediatric TB, and ART is strongly 
protective. In HIV-infected children, early diagnosis and ART initiation reduces TB 
risk.  
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INTRODUCTION  
 
Children are at high risk of progression to tuberculosis (TB) disease following 
infection with Mycobacterium tuberculosis, particularly children in the first two years 
of life, who often develop non-pulmonary forms of TB.[1] The variety of 
presentation, difficulty in obtaining samples for laboratory testing and paucibacillary 
nature of disease mean that confirming a TB diagnosis in children can be challenging. 
This adds to difficulties in understanding the natural history and epidemiology of 
disease. Recent indirect approaches to burden estimation have used mathematical 
modelling of exposure and disease progression risks to predict paediatric TB 
incidence.[2] WHO estimated that in 2014 one million children developed TB 
globally.[3] 
Although programs to prevent mother-to-child transmission (PMTCT) of human 
immunodeficiency virus (HIV) have reduced new cases of vertically infected infants, 
coverage is incomplete; in 2013, an estimated 199,000 (170,000-230,000) children 
were newly infected with HIV.[4] Children experience more rapid HIV disease 
progression than adults, making them highly susceptible to opportunistic 
infections.[5] Antiretroviral therapy (ART) can restore immune function and has 
enormously reduced morbidity and mortality among HIV-infected children. In 2015, 
World Health Organization (WHO) guidelines were revised, recommending all HIV-
infected children should initiate ART, irrespective of clinical disease stage or degree 
of immunosuppression.[6] However, ART coverage among children lags behind 
adults, with only one-third of eligible children currently on ART, compared to two-
thirds of adults.[4]  
In adults, HIV is a known potent risk factor for developing TB, with incident rate 
ratios (IRR) greater than 5 when averaged across all levels of immunodeficiency.[7] 
Evidence synthesis suggests an exponential increase in the IRR with decrease in CD4 
T-cell counts.[8 9] The effect of ART in reducing TB risk in adults living with HIV 
infection is well described.[10] This quantitative understanding of the effects of HIV 
and ART on TB progression has been widely used by modellers, e.g. in predicting the 
impact of HIV interventions on TB incidence.[9 11 12] In contrast to adults, the 
impact of HIV infection and ART on TB progression in children is poorly quantified; 
no systematic reviews have been performed to evaluate this relationship. In the 
context of revised WHO treatment recommendations, our objective was therefore to 
systematically review the paediatric HIV/TB literature to quantify the effect of HIV 
and ART on TB risk in children. 
  
METHODS  
 
This systematic review is reported in accordance with the Preferred Reporting Items 
for Systematic Review and Meta-Analyses (PRISMA) statement[13] (see 
supplementary checklist). A protocol was registered with PROSPERO (identification 
number: CRD42014014276) in October 2014. 
 
Cohort Definitions 
 
For all studies, the exposure/intervention was HIV infection, with or without ART. 
We sought studies that either: (i) reported HIV prevalence in children with TB (‘TB 
cohorts’); or (ii) reported TB disease incidence in cohorts of children with HIV (‘HIV 
cohorts’). For TB cohorts, the outcome was HIV prevalence, and the comparator was 
HIV prevalence in control groups of children without TB. For HIV cohorts, the 
outcome was TB incidence, and the comparison was between subgroups of the same 
cohort with different levels of immune suppression, or ART exposure (all HIV-
infected). 
 
Search strategy, selection criteria, data extraction 
 
To be eligible, a study had to present empirical data on more than 5 cases of TB in 
children (aged <15 years). Studies were excluded if they were not generally 
representative of paediatric TB cases in that population at that time, e.g.: studies that 
only addressed one form of TB; that only comprised hospitalized TB cases; studies 
explicitly focused on migrant populations; or autopsy studies. If the same cohort was 
published more than once, or individuals were described in more than one cohort, 
studies/children were only included once. Where explicit use of isoniazid preventive 
therapy (IPT) was stated, children receiving IPT were excluded. TB cohorts were 
excluded if the coverage of HIV testing was below 70% among TB cases. HIV 
cohorts were excluded if data were not reported that could be interpreted as an 
incidence (i.e. number of events and person-time).  
 
MEDLINE and Embase were systematically searched without language, publication, 
or date restrictions using terms designed to capture Children & TB & (HIV or ART) 
on 20/12/2014 (see Appendix for full search). A combination of MeSH and EMTREE 
headings were used with free-text terms to enhance the sensitivity of the search. We 
further searched the Cochrane Controlled Trials Register and AIDSinfo for relevant 
studies. All references in review articles found by our database search were included. 
All citations listed in Google Scholar of the five most cited review articles found by 
our database search were screened. One additional study in press at the time of our 
systematic review, was brought to our attention after presenting draft results.[14] Two 
investigators (PJD and JAS) independently assessed titles and abstracts for inclusion. 
Full texts were independently assessed for inclusion and study type by PJD and JAS 
with disagreements resolved by discussion. Two investigators extracted the data for 
TB cohorts in tandem; PJD extracted the data for HIV cohorts with 25% of data 
checked by JAS.  
 For both study designs, the following were recorded: first author, publication year, 
study years, study country, number of TB cases, age range, number of male children. 
For TB cohorts, if local TB-free controls were reported in the study, the HIV 
prevalence among control children (numerator and denominator) was extracted. Other 
data extracted from the TB cohorts included: the coverage of HIV testing, the 
numerator and denominator of HIV prevalence in TB cases and the UNAIDS 
paediatric HIV estimate for corresponding country-year (if available; mid-point and 
uncertainty range). For HIV cohorts, the following were recorded: TB incidence (with 
uncertainty range), ART coverage at enrollment, estimate of protective effect of ART 
against TB (if present), and TB incidence in any ART- or immune-related stratum 
(with uncertainty range). Co-trimoxazole use was recorded where described. TB 
incidence by age band was extracted if present. Some studies recorded immune status 
using the WHO immunological classification[6] (not-significant, mild, advanced and 
severe immunosuppression), whereas others used alternative CD4% or CD4 count 
categories, which differed between studies. Mid-points and confidence intervals 
(assumed Poisson exact) were used to infer event numbers and person-time when 
aggregation was necessary. Some studies excluded incident TB within the first few 
months on ART, stating that they sought to exclude Immune Reconstitution 
Inflammatory Syndrome (IRIS) reactions and only determine true TB incidence. 
 
Quality of individual studies was assessed using an adapted Newcastle-Ottawa quality 
assessment tool.[15] The version for case-control studies was used for TB cohorts; the 
version for cohort studies for HIV cohorts. For HIV cohorts, the quality for each 
study as input to each meta-analysis was assessed separately (Appendix pp.18-21) and 
reported as low/moderate/high quality (depending on whether few/some/most criteria 
were met) on domains of selection, comparability, and either outcome (for cohort 
studies) or exposure (for case-control studies). 
 
Statistical analyses 
 
For TB cohorts, we undertook a random-effects meta-analysis of the odds ratio (OR) 
for HIV prevalence given TB among those studies reporting HIV prevalence in 
controls. This OR can be interpreted as an incidence rate ratio (IRR) for developing 
TB disease if HIV positive[7] (Appendix p.7). We produced funnel plots to assess 
evidence of publication bias.  
 
For TB cohorts where UNAIDS estimates of national HIV prevalence in the <15 year 
age group were available for the same year and country as the study, we undertook a 
Bayesian meta-analysis using both the UNAIDS data and control data. This analysis 
modelled the relationship between UNAIDS HIV prevalence and HIV prevalence in 
study controls from studies where both were available, and used this relationship to 
predict individual study ORs where controls were not available. For comparison, a 
Bayesian version of the meta-analysis of studies with controls was conducted 
(Appendix pp.8-11). 
 
For HIV cohorts reporting TB incidence by immune stage, we undertook a random-
effects meta-analysis of the IRR for each stratum relative to the ‘not-significant’ 
WHO immune stage. For HIV cohorts reporting incidence by >1 CD4% category 
(using the mid-point of the CD4% category in which the incidence was reported), or 
an analysis of the relation between CD4% and IRR for TB, we undertook a Bayesian 
meta-analysis to estimate the gradient of logarithmic IRR with respect to CD4% 
(Appendix pp.13-15). We averaged the IRR implied by this point estimate over 
CD4% between 0% and 50% to compare with our IRR from the TB cohort analysis. 
For HIV cohorts reporting an estimate of the protection against TB from ART as a 
hazard ratio (HR), we performed a random-effects meta-analysis. For HIV cohorts 
reporting TB incidence by >1 category of time-since-ART-initiation, we fitted a non-
linear mixed effects model to estimate the temporal dependence of ART protection, 
using the mid-point of the time window in which the incidence was reported to model 
incidence (Appendix pp.15-16). 
 
Bayesian techniques were employed where greater flexibility was required over 
standard software implementations to utilise all the data. All statistical analyses were 
undertaken using in R;[16] random effects meta-analysis was performed using the 
rma command in the metafor package implementing the restricted maximum-
likelihood estimator.[17] 
 
RESULTS  
 
Search results 
 
The systematic review process is presented in Figure 1. Of the 311 full-text articles 
screened, 65 were included in this review. The most common reasons for exclusion 
were HIV test coverage <70% for TB cohorts (n=46), and TB incidence not reported 
for HIV cohorts (n=22). Of the 65 included studies, 42 were classified as TB cohorts 
(see Table 1), 22 were classified as HIV cohorts (see Table 2), and 1 study included 
both a TB and HIV cohort.[18] Thirty-one of the 42 TB cohorts (74%) and 17 of the 
22 HIV cohorts (77%) were from sub-Saharan Africa. 
 
Of the TB cohorts, 8 included HIV prevalence in controls without TB and could be 
used in the random-effects meta-analysis; 35 had relevant UNAIDS estimates and 
could be included in the Bayesian meta-analysis, including all 8 studies with controls.  
  
Of the HIV cohorts, 7 could be included in the meta-analysis of CD4% influence, 3 
could be included in the analysis of the influence of immunological staging, 10 were 
included in the analysis of time on ART, and 6 were included in the pooled estimate 
of ART efficacy against TB. Only 3 HIV cohorts reported co-trimoxazole use.[14 19 
20]  
 
HIV prevalence in TB cohorts ranged between 5% and 94% (Appendix p.5). TB 
incidence in HIV cohorts ranged from 0.3 to 25.3 per 100 person-years (Appendix 
p.6). Insufficient data were available in either group of cohorts to stratify results by 
age.  
 
Tables 
Table 1: TB cohorts (ns = not stated; na=not applicable; *=data from years with high enough HIV testing rates used; age range obtained 
where stated, for eligibility otherwise; ** adapted Newcastle-Ottawa score for case-control studies with some questions (and the 
comparability domain) not applicable to studies without controls: A=high quality; B=moderate quality; C=low quality; see Appendix 
pp.18-19, 24-25) 
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Ade, 2013[21] Benin 2009-2011 
Cross-sectional study reviewing of all children treated for TB in one city 
over a three year period. na na 182 167 49 88 0-14 C/-/C 
Berggren 
Palme, 2004[22] Ethiopia 
1995-
1997 
Prospective study recruiting all children investigated for TB at one 
hospital over a 13 month period na na 355 355 54 ns
 0-14 B/-/C 
Berggren 
Palme, 2001[23] Ethiopia 
1995-
1997 
Case control study, prospectively recruiting all children diagnosed with 
TB over a one year period at one children's hospital, with a control group 
recruited concurrently amongst children undergoing elective surgery 
122 2 377 377 47 186 0-14 B/A/A 
Bhat, 1993[24] Zambia 1991-1991 
Case control study, prospectively recruiting all children diagnosed with 
TB over a nine month period at one hospital, with a control group 
recruited from outpatients clinics and amongst surgical inpatients 
134 18 116 96 36 58 0-14 B/C/A 
Bobossi-
Serengbe, 
2005[25] 
Central 
African 
Republic 
1998-
2000 
Retrospective analysis of all children treated for TB over a two year 
period in one hospital clinic na na 284 284 211 153 1-14 C/-/C 
Campos-
Herrero Navas, 
1997[26] 
Gran Canaria 1986-1994 
Retrospective analysis of all children treated for TB over a nine year 
period on the island na na 49 49 1 ns 0-14 B/-/C 
Cathebras, 
1998[27] 
Central 
African 
Republic 
1997-
1998 
Prospective study in which all patients (adults and children) treated for 
TB over a three month period at one hospital were tested for HIV na na 37 37 4 ns 0-14 B/-/C 
Chintu, 
1993[28] Zambia 
1990-
1991 
Case control study of all children treated for TB over an 18 month period 
in one teaching hospital. Controls were recruited from the emergency 
department or inpatient surgical wards 
242 26 265 237 88 125 0-15 B/C/A 
Chintu, 
1998[29] Zambia 
1992-
1993 
Case control study of all patients (adults and children) presenting with 
diarrhoea over an 8 month period at one teaching hospital. Cases were 
HIV-infected with controls HIV-uninfected. Paediatric analysis restricted 
to children under 5 years 
na na 4 4 3 ns 1-5 C/-/C 
Chintu, 
1995[30] Zambia 
1990-
1991 
Prospective study of all children under 5 years admitted to the ward of a 
teaching hospital. Comparisons made between children with HIV and 
children without HIV, with respect to proportion with TB. 
160 15 61 61 42 ns 0-5 B/C/A 
Daniel, 
2007[31] Nigeria 
1999-
2003 
Retrospective study of all children diagnosed with TB at one TB centre 
over a five year period. na na 76 76 8 46 1-14 A/-/A 
Edwards, 
2007[32] 
Democratic 
Republic of 
Congo 
2002-
2003 
Retrospective study of all children treated for TB at one hospital over a 
one year period. na na 110 91 42 ns 0-15 B/-/C 
Espinal, 
1996[33] 
Dominican 
Republic 
1991-
1994 
Prospective study of all children aged 18-59 months treated for TB at two 
institutions over a three year period na na 204 189 11 92 1-5 B/-/C 
Feldacker, 
2012[34] Malawi 
2008-
2010 
Retrospective study of all patients (adults and children) treated for TB at 
one TB treatment centre over a three year period. na na 364 338 148 168 0-14 C/-/C 
Gava, 2013[35] Brazil 1997-2006 
Retrospective review of routinely collected data for all children treated 
for TB in one state over a ten year period na na 356 356 3 183 0-14 C/-/C 
Geoghagen, 
2004[36] Jamaica 
1999-
2002 
Retrospective review of all children 0-12 years treated for TB at one 
hospital over a four year period na na 26 24 11 16 0-12 C/-/C 
Henegar, 
2013[37] 
Democratic 
Republic of 
Congo 
2006-
2007 
Prospective study of all patients (adults and children) starting treatment 
for TB at 14 clinics over a 17 month period na na 830 701 59 398 0-14 C/-/C 
Hesseling, 
2009[38] South Africa 
2004-
2006 
Prospective laboratory data collected from 3 hospitals over a three year 
period, used to estimate the incidence of TB in infants (<12months) with 
HIV and without HIV 
na na 245 175 53 133 0-1 C/-/C 
Hussain, 
2007[39] India 
2003-
2004 
Prospective study of all children admitted to one hospital for the 
treatment of TB, over a two year period na na 270 270 23 154 0-15 C/-/C 
Iriso, 2005[40] Uganda 2003 Cross-sectional study of all children aged 2-60 months, investigated for TB at one hospital over a 12 week period na na 126 126 62 63 0-5 B/-/C 
Jain, 2013[41] India 2010-2012 
Prospective study of all children <5 years investigated for suspected TB, 
at one hospital over a 20 month period na na 26 21 6 15 0-5 C/-/C 
Jensen, 
2012[42] Spain 
1997-
2008 
Case-control study. Details of all HIV-infected children (<17 years) 
hospitalised anywhere in the country over a 12 year period were extracted 
from a central database. 4 HIV-uninfected controls, matched on age and 
gender, were extracted for each case. Rates of mycobacterial diseases 
were compared between cases and controls 
na na 30 30 20 ns 0-17 C/-/C 
Llerena, 
2010[43] Colombia 
2001-
2009 
Cross-sectional study of data from one laboratory of all children with 
culture-confirmed TB diagnosed over an 8 year period na na 128 128 7 62 0-14 C/-/C 
Luo, 1994[44] Zambia 1991-1992 
Prospective study of all children treated for TB at one hospital over an 8 
month period. Controls were children with traumatic injuries, selected 
from the emergency department or from the surgical wards 
167 16 120 110 67 70 0-14 B/C/A 
Madhi, 
1999[45] South Africa 
1996-
1997 
Prospective study of all children (2 months to 12 years) treated for TB at 
hospitals attached to an academic department of paediatrics over a 5 
month period. 
na na 130 130 52 85 0-12 C/-/C 
Mehta, 
2011[46] Tanzania 
2005-
2007 
Randomised controlled trial of multivitamin supplementation in children 
with TB. All children (6 weeks to five years) treated for TB at one clinic 
were included and randomised over a 30 month period 
na na 255 255 87 139 0-5 B/-/C 
Miranda, 
2011[47] Brazil 
2000-
2006 
All cases of paediatric TB recorded on a state register over a 6 year 
period were included. Matching with the state AIDS database then 
performed 
na na 411 411 27 191 0-14 C/-/C 
Mukadi, 
1997[48] Côte d'Ivoire 
1994-
1995 
Prospective study of all children (0-9 years) diagnosed with TB in two 
TB centres and two hospitals over a 21 month period 161 0 161 160 31 84 0-9 A/A/A 
Berggren 
Palme, 2002[49] Ethiopia 
1995-
1997 
Prospective study of all children diagnosed with TB at the outpatient 
clinic or from the inpatient wards at one paediatric hospital over a 13 
month period 
na na 517 517 58 259 0-14 B/-/C 
Panigatti, 
2014[50] India 
2009-
2010 
Prospective study of all children (0-12 years) diagnosed with TB at one 
hospital over an 18 month period, treated using a DOTS regimen na na 93 93 7 45 0-12 C/-/C 
Rachow, 
2012[51] Tanzania 
2008-
2010 
Prospective study of all children diagnosed with TB at one research 
facility over a 31 month period na na 164 164 84 86 0-14 C/-/C 
Ramos, 
2010[52] Ethiopia 2007 
Retrospective data collection from TB registers and treatment cards of all 
patients (adults and children) treated for TB over a 10 year period at one 
private hospital* 
na na 187 158 149 ns 0-14 C/-/C 
Rose, 2012[53] Tanzania 2008-2010 
Prospective study of all children with suspected TB at one district 
hospital over a 27 month period 93 22 33 33 18 24 0-14 A/C/A 
Sassan-
Morokro, 
1994[54] 
Côte d'Ivoire 1989-1990 
Prospective study of all children diagnosed with TB at two outpatient 
treatment centres over an 18 month period na na 289 289 34 ns 1-14 B/-/C 
Schaaf, 
2014[55] South Africa 
2009-
2011 
Retrospective study of all children (<13 years) with culture-confirmed TB 
at one teaching hospital over a two year period na na 340 288 63 177 0-13 C/-/C 
Seddon, 
2012[56] South Africa 
2007-
2009 
Retrospective study of all children (<13 years) with culture-confirmed TB 
at one teaching hospital over a two year period na na 294 217 63 156 0-13 C/-/C 
Shahab, 
2004[57] India 
1999-
2000 
Prospective study of all children (<12 years) treated for TB in the 
outpatient and inpatient departments of one tertiary hospital over a 17 
month period 
na na 250 250 5 174 0-12 C/-/C 
Thomas, 
2014[58] South Africa 
2009-
2010 
Prospective study of all children (6 months to 12 years) with possible 
probable or confirmed TB recruited from outpatient and inpatient settings 
of one district hospital over a 17 month period 
na na 33 26 17 19 0-12 B/-/C 
Yassin, 
2011[59] Ethiopia 2009 
Cross-sectional study of all children (1-15 years) with TB symptoms and 
a TB source case who were investigated at two health centres and one 
hospital. TB-exposed but asymptomatic and unexposed children were 
also recruited as controls. 
153 3 164 141 14 105 1-15 A/C/B 
Kwara, 
2015[60] Ghana 
2012-
2014 
 
Prospective pharmacokinetic study of all children (3 months to 14 years) 
starting treatment for TB disease at one teaching hospital over a two year 
period 
 
na na 62 62 28 32 0-14 C/-/C 
Lopez-Varela, 
2015[61] Mozambique 
2011-
2012 
 
Prospective study from one heath district where all children (<3 years) 
with presumptive TB were recruited over a 12 month period 
 
na na 32 32 18 15 0-3 B/-/C 
Perfura Yone, 
2012[62] Cameroon 
2005-
2010 
 
Retrospective study all children (<15 years) diagnosed with TB and 
treated as inpatients at one hospital over a 5 and a half year period 
 
na na 101 101 25 50 0-15 B/-/C 
 
  
 Table 2: HIV cohorts (na=not applicable; ns=not stated; ** adapted Newcastle-Ottawa tool for cohort studies: A=high quality; 
B=moderate quality; C=low quality; see Appendix pp.19-21, 26-27) 
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Abuogi, 
2013[63] Kenya 
2009-
2010 
Prospective cohort study of HIV-infected children (6 weeks to 
14 years, some on ART and some not) followed up for the 
incidence of clinically diagnosed TB. Study at two urban 
clinics with children recruited over a two year period 
10 686 720 1.39 (0.75-2.58) 74 322 0-14 B/A B/C/A na na na 
Alarcon, 
2012[64] Brazil 
2002-
2007 
Prospective cohort study of HIV-infected children (<21 years) 
at 17 sites in Latin America; children recruited over a five 
year period and followed for the incidence of a number of 
opportunistic infections, including TB 
7 731 2523 0.28(0.07-0.48) 67 325 0-22 B/B na na na na 
Auld, 
2014[65] 
Cote 
D'Ivoire 
2004-
2008 
A nationally representative retrospective cohort study of 
children (<15 years) starting ART over a five year period at 
29 facilities 
56 1960 4190 1.34(1.03-1.74) 100 1058 0-14 C/C na C/A/C B/C/C na 
Bakeera-
Kitaka, 
2011[66] 
Uganda 2003-2006 
Retrospective cohort study of children and adolescents 
starting ART over a three and a half year period at one 
specialist clinic 
311 1806 1690 18.4(17.1-20.3) 100 932 ns C/C na na B/C/C B/A/C 
Braitstein, 
2009[67] Kenya 
2001-
2007 
Retrospective observational study of all children (<13 years) 
enrolled in a network of HIV clinics over a 5 year period 765 6301 4368 17.6(16.3-18.8) 19 3144 0-13 C/C na na B/C/C B/A/C 
Brennan, 
2014[68] 
South 
Africa 
2004-
2011 
Retrospective cohort of all children (<19 years) on ART 
enrolled over a 7 year period at 12 urban clinics 113 3329 2828 4.0(3.3-4.8) 100 1608 0-18 C/C na C/A/C B/A/C na 
Ciaranello, 
2014[69] East Africa 
2002-
2008 
All HIV-infected infants (<12 months) enrolled over a 6 year 
period at 7 sites across 3 countries 128 847 738 17.4 (14.5-20.6) 0 418 <1 C/C na C/C/C na na 
Crook, 
2016[14] 
Uganda, 
Zimbabwe 
2007-
2012 
Randomised controlled trial assessing different monitoring 
strategies for providing ART. All HIV-infected children (3 
months to 17 years) enrolled from 4 centres in 2 countries 
over an 18 month period 
69 969 3632 1.9(1.5-2.4) 100 488 0-17 B/B na B/A/B A/C/B na 
Curtis, 
2012[19] 8 countries 
2002-
2010 
Data from 25 HIV treatment centres in 8 countries collected 
prospectively over an 8 year period. Adults and children 
included if starting ART at one of the centres. Data from 
children (<15 years) disaggregated from adults 
140 3946 1687 8.3(8.1-8.6) 100 ns 0-15 C/C na na B/C/C na 
Dankne, 
2001[70] USA 
1988-
1998 
Data from 13 studies over a period of 10 years with children 
(<21 years) included. From pre-ART period. Wide range of 
opportunistic infections assessed 
27 3331 6750 0.4(0.3-0.6) 0 1852 0-21 C/C na C/C/C na na 
De Beaudrap, 
2013[71] 
Burkina 
Faso/Cote 
d'Ivoire 
2006-
2007/2
000-
2004 
Pooled data from a clinical trial (recruited over 1 year) and 
observational cohort (recruited over 4 years). Children (15 
months to 15 years) enroled at initiation of ART and followed 
for two years 
10 188 355 2.9(1.4-5.1) 100 66 ns C/A na C/C/A B/C/A na 
Edmonds, 
2009[72] 
Democratic 
Republic of 
the Congo 
2004-
2008 
Prospective study of children (<18 years) enroled from one 
hospital clinic over a three and a half year period. All children 
ART-naive at baseline with some starting ART during follow 
up 
81 364 596 13.6(10.8-16.9) 0 172 0-18 B/B B/C/B na A/C/B A/A/B 
Gray, 
2014[73] 
South 
Africa 
2005-
2011 
Control (placebo) arm of a randomised controlled trial of 
isoniazid preventive therapy. Children (over 8 weeks) 
recruited over a 4 year period from 3 sites 
7 82 240 2.9 (1.2-6.0) 100 42 ns A/B na na na na 
Kouakoussui, 
2004[74] 
Cote 
D'Ivoire 
2000--
2003 
All children recruited from 1 clinic and followed up for 
incident TB. All children in the study initiated ART at some 
point in the study to provide pre- and post-ART TB 
incidences. 
7 282 206 3.4 (1.5-6.7) 65 153 1-16 C/B na C/C/C na na 
Li, 2013[75] Tanzania 2004-2011 
Prospective study of all children (<15 years) from 28 clinics 
recruited over a 7 year period. ART started based on local 
guidelines over follow up 
376 5040 7221 5.2(4.7-5.8) 51 2460 0-14 B/C B/A/C na A/A/C A/A/C 
Martinson, 
2009[76] 
South 
Africa 
1994-
2006 
Retrospective cohort of children (<15 years) recruited from 4 
clinics over a 12 year period. Incidence determined for the 
period pre- and post-ART 
281 1132 1713 12.3 (9.8-12.6) 2 563 0-14 B/C na na na A/A/C 
Prasitsuebsai, 
2014[77] SE Asia 
1993-
2009 
Retrospective and prospective cohort of HIV-infected 
FKLOGUHQ\HDUVIURPFOLQLFVLQcountries in SE Asia. 
Recruited over a 16 year period. Wide range of OIs assessed. 
Period covered before ART, during mono- or dual-therapy 
and on HAART 
477 2280 1826 21.5(19.4-23.7) 7 1136 0-18 C/C na na na na 
Thomas, 
2000[78] 
USA 
(NYC) 
1989-
1995 
Retrospective study in HIV-exposed and -infected children 
enrolled in a longitudinal study. TB cases determined by 
review of clinical records and by linkage to local TB registry. 
Registry data assessed for a 6 year period 
45 1426 7384 0.61 (0.44-0.82) 0 475 0-12 B/B na na na na 
Walters, 
2008[79] 
South 
Africa 
2003-
2005 
Chart review of all children (<13 years) starting HAART at 
one hospital over a 3 year period and followed up until the 
end of the study period for incident TB. Cases defined as pre-
HAART (if in the 9 months prior to HAART initiation) or 
post HAART 
10 290 546 25.1(21.1-29.6) 0 142 0-14 C/A na na na na 
Walters, 
2014[80] 
South 
Africa 
2003-
2010 
Retrospective cohort of all children (<2 years) starting 
HAART at one hospital over an 8 year period. Children 
divided into those developing TB-IRIS (developing TB with 3 
months of starting HAART) and those with incident TB 
(developing TB after 3 months) 
55 341 855 25.3(22.0-28.9) 0 161 <2 B/C na na A/C/C na 
Yirdaw, 
2014[81] Ethiopia 
2007-
2010 
Retrospective cohort study of the electronic records of all 
patients (adults and children) starting ART over a three year 
period in 5 hospitals in one region of Ethiopia. Patients 
followed until the end of the study period and the 
interventions of ART and IPT evaluated. Incidence stratified 
by age enabling extraction children (<15 years) 
23 475 1099 2.1(1.3-3.1) ns ns 0-15 B/C na na na A/C/C 
Zar, 2007[20] South Africa 
2003-
2004 
Double blind RCT evaluating the impact of IPT on TB 
incidence in HIV-infected children (aged older than 8 weeks). 
Children recruited from two sites with the trial stopped after 
17 months. Data on TB incidence taken from placebo arm. 
13 131 56 23.4(12.4-50.0) 8 74 0-14 C/C na na na na 
 
Quality assessment 
 
TB cohorts were of low and moderate quality for our analysis (Table 1). Studies 
without controls could not be classed higher than moderate quality on selection and 
low quality on exposure. Controls were often drawn from clinic populations in the 
same context. In around half of studies, TB was defined only by a decision to treat. 
 
HIV cohorts were typically of low quality for our analyses (Table 2). Most studies 
were clinic-based and not necessarily community-representative; prevalent TB was 
not always ruled out at baseline; there were often shortcomings in follow-up or case 
definitions for TB.  
Meta-Analyses for TB cohorts 
 
The random-effects meta-analysis of TB cohorts for the odds of having HIV in TB 
cases included 8 case-control studies (Figure 2). In total, 1,215 TB cases and 1,232 
non-TB controls were included. The pooled estimate for the OR was 7.9 (95% 
confidence interval [CI]: 4.5 - 13.7), and the I-squared heterogeneity statistic was I2 = 
69.8% (see Figure 2). A funnel plot corresponding to this analysis is presented in 
Appendix p.8.  
 
The Bayesian meta-analysis included 35 studies (including all 8 with controls) and 
produced a pooled estimate of the OR for HIV among children with TB of 7.0 (95% 
credible interval [CrI]: 5.7 – 8.5), see Figure 3. This analysis also found the paediatric 
HIV prevalence in controls to be substantially higher than national UNAIDS 
estimates of HIV prevalence in the <15 year age group, with an odds ratio of 7.3 
(95%CrI: 5.9 – 8.8). For studies that lacked explicit control groups (indicated in red in 
Figure 3), this analysis also predicted what the odds ratios would have been for HIV 
prevalence in TB cases versus HIV prevalence in a putative control group of 
comparable children without TB. The pooled estimates of effect for the analyses with 
and without the UNAIDS data were similar (Appendix p.11).  
Meta-analyses for HIV cohorts 
 
For HIV cohorts, the random effects meta-analysis of TB incidence in children with 
severe compared to non-significant immunosuppression according to WHO 
categorisation gave an IRR of 5.0 (95%: 4.0 – 6.0) with I-squared heterogeneity 
statistic I2 = 87.1% (see Figure 4). The Bayesian meta-analysis of the gradient of the 
logarithmic IRR with respect to CD4% yielded a pooled estimate of -0.063 (95%CrI: 
-0.188 – +0.063), corresponding to a reduction in IRR of 0.94 (95%CrI: 0.83 – 1.07) 
per one percentage-point increase in CD4% (see Figure 5). This point estimate 
implies a mean IRR of 7.1 over CD4 percentages ranging between 0% and 50%. The 
random effects meta-analysis of protection from ART yielded a pooled hazard ratio 
estimate of 0.30 (95%CI: 0.21 - 0.39) with I-squared heterogeneity statistic I2 = 79% 
(see Figure 6).  
 
The non-linear mixed effects regression for the protection from ART by time-since-
initiation estimated a rapid initial decline in incidence over the first year, reaching a 
plateau as protection from ART fully establishes over around two years at a pooled 
asymptotic hazard ratio of 0.10 (95%CI: 0.04 - 0.25), giving a mean hazard ratio over 
the first 30 months on ART of approximately 0.25 (see Figure 7).  
 
  
DISCUSSION 
 
In this systematic review, we identified cohorts of children with TB and cohorts of 
children with HIV. We observed a high but variable prevalence of HIV infection in 
the TB cohorts, and a very high TB incidence in the HIV cohorts. Accounting for 
background risk of TB, we found, as in adults, HIV was important risk factor for TB 
and that TB risk increases with immunosuppression. ART was strongly protective 
against TB, but took two years for full potential of protection against TB to be 
realized.  
 
In adults, IRRs for TB given HIV around 6 have been estimated for populations with 
generalized HIV epidemics,[7] corresponding to most newly diagnosed adult TB 
cases having HIV infection. Our IRR for children is comparable, but lower HIV 
prevalence is seen in children with TB due to a lower overall paediatric HIV 
prevalence. In adults, meta-analyses of cohorts of HIV patients suggest exponentially 
increasing IRR for TB with declining CD4 cell count,[9] and current CD4 cell counts 
on ART strongly predict TB incidence.[82] A systematic review and meta-analysis of 
the protective effect of ART against TB found a hazard ratio of 0.35 (0.28-0.44) 
across all baseline CD4 cell counts,[10] comparable to our result for children. Long-
term follow-up of adults on ART suggests 4-5 years for protection against TB to 
become fully established.[83] Our analysis suggests that protection against TB in 
children on ART establishes more rapidly (1-2 years), consistent with faster CD4 
reconstitution among children[84] compared to adults.[85 86]  
 
Our findings have implications for patient care, guidelines, TB programmes, and 
mathematical modelling. For clinicians, TB risk with HIV and ART informs patient 
treatment and appropriate family counseling. For TB programme officers, 
understanding risks informs resource allocation, and service configuration for HIV 
testing and treatment. These findings can inform evidence-based guideline 
development; timely given the recent revision of WHO ART guidelines advocating 
universal treatment for children with HIV, irrespective of clinical and immunological 
stage. Finally, these data inform models of burden estimates and for evaluating the 
impact of interventions, in relation to HIV and ART.  
 
Our review has limitations. Although our search strategy was comprehensive, studies 
were excluded if not representative of children with TB in that context. The cohorts 
identified were generally of low quality for our analyses, the most common 
shortcomings being around population representativeness and TB case-definitions. 
The majority of studies were from sub-Saharan Africa, where 90% of all HIV-
infected children live, and the findings may not generalize to other regions. The 
studies spanned a long time period, and may not be representative of the current era. 
Statistical heterogeneity was high for summary statistics from both TB cohorts and 
especially HIV cohorts, reflecting diverse study settings and dates, and unreported 
clinical and methodological heterogeneity. However, measures of heterogeneity were 
comparable with those from similar studies.[87] There were a number of limitations 
of our meta-analyses of TB cohort data. Controls were often not from the general 
population. This may partially explain the differences between HIV prevalence in 
study controls and UNAIDS paediatric HIV prevalence estimates. However, UNAIDS 
reports country-level estimates for children aged <15 years, which are not likely to 
reflect the HIV prevalence in younger children local to these studies. Difficulties in 
diagnosing TB in children with HIV may have led to differential detection of cases by 
HIV status, affecting the IRR from case-control TB cohorts. Moreover, estimates of 
the increased risk of TB progression will be confounded by higher exposure due to 
sharing households with HIV-infected parents, themselves at increased risk of TB. 
This makes it difficult to differentiate the direct biological impact of HIV from 
indirect effects. Implicitly, our analyses assume the same relationship between HIV, 
ART and TB holds regardless of population TB or HIV prevalence, which may not be 
the case across the very wide range of prevalences in the studies included.  
 
A number of limitations apply to our meta-analyses of HIV data. CD4 percentage 
categories were disparately reported, and we used category mid-points for analyses of 
CD4% and time-on-ART. Many studies allowed for unmasking of prevalent TB at 
ART initiation by excluding a certain period after initiation from comparisons, but 
this varied between studies. However, excluding all children diagnosed with TB soon 
after initiating ART may underestimate early incident TB in children who are still 
highly immunosuppressed. Only three HIV cohorts reported co-trimoxazole use,[14 
19 20] but as guidelines have varied over time and by setting, co-trimoxazole use may 
have been under-reported. Confounding by indication was not considered in estimates 
of ART protection (except for Edmonds et al.[72]), and choice of covariates varied 
between studies. Our direct meta-analysis of the protective effect of ART was not 
able to include how long children had been on ART, and will average over the 
different distribution of treatment durations between studies. 
 
We were not able to analyse age effects on TB, as data were seldom reported with 
multiple age stratifications. Our analysis of protection by time-on-ART may be 
confounded by age. Young children have particularly high TB progression risk, in 
part due to immature cell-mediated immune responses.[1] The impact of age on 
efficacy of ART is also complex, as early ART initiation, at a better baseline immune 
status, leads to better immune reconstitution (although adherence can be challenging 
at the youngest ages due to a paucity of palatable formulations).[84 88 89] The studies 
in our review were conducted over years when ART treatment guidelines, availability 
and formulations were evolving. The relevance of our findings to current universal 
treatment recommendations needs careful consideration; individual patient data meta-
analysis would be highly informative on the impact of host characteristics on risk of 
TB, in particular the age of the child and age at which ART was initiated. As children 
are started on ART at higher CD4 values, the protective benefit of ART against TB 
may be lower. 
 
Despite these limitations, internal consistency between results from different analyses 
increases the confidence in our conclusions. Our IRR from TB cohorts is comparable 
with the estimate of ‘Severe’ compared with ‘Not Significant’ immune staging, 
recognising that HIV may confer an increased risk of TB even before 
immunosuppression is clinically evident. The mean IRR over a range of CD4 
percentages between 0% and 50% was 7.1 using the risk gradient point-estimate from 
our CD4 analysis – close to our IRR estimate for all HIV from TB cohorts. The mean 
protection against TB over the first 30 months on ART was 0.25 – comparable to our 
meta-analysis of estimates of protection (although these analyses ultimately stem 
from the same data). The decline in TB rates by time-on-ART occurred on a similar 
timescale to the analysis presented in Li et al.,[75] although to a lower final value. 
Comparing our HIV and ART risk results suggests that children commencing ART 
are at higher risk of TB than HIV-uninfected children initially, but our results are too 
uncertain to specify whether long-term TB risks ART return to those of an HIV-
uninfected child. For adults, TB risks established on long-term ART remain elevated 
over those of HIV-uninfected individuals.[83] 
 
It is important to place ART in the context of other public health interventions. Our 
results suggest early diagnosis of infants and young children with HIV, followed by 
immediate ART, will reduce the pool of highly susceptible children and consequent 
progression to TB disease, providing further impetus to scale-up coverage among 
paediatric ART programmes. High HIV prevalence in the TB cohorts and high TB 
incidence in the HIV cohorts suggest that all children diagnosed with TB should be 
tested for HIV infection and all children with HIV should be regularly screened for 
TB disease. Scale-up of PMTCT will lead to fewer children becoming infected with 
HIV and is likely to be one of the most effective public health strategies to reduce 
paediatric HIV/TB; similarly, prompt diagnosis of TB in HIV-infected adults will 
reduce the risk of TB transmission to their HIV-infected children. TB control in adults 
more generally,[90] and infection control measures, will reduce the risk of TB 
transmission to vulnerable children. Isoniazid preventive therapy appears similarly 
effective at reducing TB incidence in HIV-infected children (around 70% reduction in 
incidence),[20 73] and evidence suggests that use in conjunction with ART is more 
protective than either intervention alone.[91] Evidence for the benefit of co-
trimoxazole in preventing incident TB in children is emerging;[14] since it is now 
recommended long-term, co-trimoxazole prophylaxis may also help to reduce TB 
incidence among HIV-infected children on ART.  Improving nutritional status among 
HIV-infected children may also be beneficial, as there is a high risk of TB in the 
context of malnutrition. Although individually these interventions are likely less 
effective than ART, their combination can be expected to protect the biggest number 
of children from developing TB.  
 
 
Conclusions  
 
Our results indicate that HIV infection is a potent risk factor for TB in children, with a 
gradient of risk by indices of immunosuppression. ART is strongly protective against 
TB in children with HIV infection, taking up to two years for protection to become 
fully established, underscoring the importance of prompt ART initiation. 
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FIGURE CAPTIONS 
 
 
Figure 1: PRISMA flow chart for systematic review (*One study included both a 
TB and HIV cohort[18]) 
 
Figure 2: Forest plot for meta-analysis of HIV risk in children aged <15 years 
with prevalent tuberculosis – studies with controls. (I2 = 69.8%) 
 
 
Figure 3: Forest plot for Bayesian meta-analysis of HIV risk in children aged 
<15 years with prevalent tuberculosis. Where studies lacked their own controls, 
UNAIDS national HIV prevalence data were used to model HIV prevalence in 
controls based on those studies with both controls and UNAIDS estimates (red). 
Meta-analysis for studies with controls only are shown in blue; meta-analysis for 
studies using UNAIDS estimates of paediatric HIV prevalence are shown in red. 
 
Figure 4: Relative tuberculosis incidence in children aged <15 years with HIV by 
WHO immunological staging. (I2 = 87.1%) 
 
Figure 5: Forest plot for meta-analysis of relation between incidence rate ratio 
for tuberculosis incidence and CD4 percentage in children aged <15 years. 
 
 
Figure 6: Forest plot of protection on ART against tuberculosis incidence in 
children <15 years with HIV infection. (I2 = 79.0%) 
 
 
Figure 7: Meta-regression of protection from tuberculosis incidence in children 
<15 years by time-on-ART, and re-aligned incidence estimates from studies. 
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